The coronavirus vaccine developed by Oxford university and AstraZeneca has shown promising results in the first phase of its clinical trials.
The eagerly awaited study, published in The Lancet on Monday, showed that the AZD1222 vaccine generated “robust immune responses” and was tolerated by all patients.
The results raise hopes that the inoculation might prevent disease, but experts warned that there was a long way to go to prove its safety and effectiveness.
您已阅读11%（462字），剩余89%（3867字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。